Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a ...

Indian pharma companies are challenging Novo Nordisk's semaglutide patents in court, which could pave the way for cheaper ...

Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...

Novo Nordisk slashes Wegovy prices by 50% for cash-paying patients amid Trump's pressure on drugmakers to reduce costs.

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Wegovy is now approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Like semaglutide, the new drug known as ecnoglutide is glucagon-like peptide-1 receptor agonist. In simple terms, they both ...

The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. About 14.9 million U.S.

An audit by the Daily Mail has found that at least 188 severely obese youngsters around England are now being prescribed ...

Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

Unauthorized use, distribution, and employment of AI-based tools to utilize copyright-protected materials constitutes an ...